Cell-dependent antithrombotic effect of tranexamic acid
By
Kata Balog Virág
Petra Csikós
Alexandra Raska
Barbara Baráth
Kristóf Molnár
Natalia Nikolova
Kiril Tenekedjiev
Krasimir Kolev
Nikolett Wohner
May 26, 2026
Clinical Scorecard: Cell-mediated antithrombotic properties of tranexamic acid
At a Glance
Category Detail
Condition Key Mechanisms Target Population Patients undergoing surgery, trauma, or experiencing postpartum hemorrhage, as indicated in the source. Care Setting
Key Highlights
TXA reduced the odds of venous thrombus formation by 90% (source needed). TXA did not alter thrombus mass once clots formed (source needed). TXA decreased thrombin generation in whole blood but not in platelet-rich plasma (source needed). TXA suppressed the rise in MCP-1 induced by stenosis (source needed). TXA did not impair primary hemostasis (source needed). Guideline-Based Recommendations
Diagnosis
Assess thrombus formation risk in patients receiving TXA (source needed). Management
Use TXA to reduce bleeding in trauma and surgery without increasing thromboembolic risk (source needed). Monitoring & Follow-up
Monitor thrombin generation and inflammatory markers in patients receiving TXA (source needed). Risks
Consider potential risks of thromboembolism based on route of administration and patient factors (source needed). Patient & Prescribing Data
TXA is effective in reducing bleeding mortality, but its prophylactic use should be context-dependent (source needed).
Clinical Best Practices
Administer TXA shortly after bleeding starts for optimal effect (source needed). Evaluate the context and timing of TXA administration to maximize benefits (source needed). Related Resources & Content
